Table 1.
Frequency, 5-year prognosis, and immunohistochemistry findings for each classified entity of CTCL. Data compiled from various tables in Atlas of Cutaneous Lymphomas: Classification and Differential Diagnosis [3], Kempf et al. [4], and Guitart et al. [5].
| Entity Name | Frequency (% of T-Cell Lymphomas) | 5-Year Prognosis (%) | Immunohistochemistry Findings | |||||
|---|---|---|---|---|---|---|---|---|
| CD3 | CD4 | CD8 | CD30 | CD56 | Other | |||
| MF | 65% | 75–98%, can vary by subtype | + | + | - (rarely +) | - | - | CD25- |
| SS | 4% | 10–33% | + | + | - | - | - | CD26-, CD27+ |
| LyP: Type A,C | 16% | 100% | + | + | - | + | - | ALK-, CD15- |
| LyP: Type B | + | + | - | - | - | ALK- | ||
| LyP: Type D | + | - | + | + | - | ALK-, βF1+ | ||
| PCALCL | 10% | 90% | + | + | - | + | - | ALK- |
| SPTCL | 1% | 85–90% | + | - | + | ± | - | βF1+ |
| PCGDTL | <1% | N/A, median survival is 15 months | + | - | ± | ± | + | Beta F1-, TCRγ+ |
| CD8+ AECTCL | <1% | 18% | + | - | + (rarely -) | - | - | CD45RA- or partially +, βF1+ |
| Acral CD8+ TCLPD | <1% | 75–100% | + | - | + | - | - | |
| CD4+ SMCLPD | <1% | >90% | + | + | - | - | - | |
MF: mycosis fungoides, SS: Sézary syndrome, LyP: lymphomatoid papulosis, PCALCL: primary cutaneous anaplastic large cell lymphoma, SPTCL: subcutaneous panniculitis-like T-cell lymphoma, PCGDTL: primary cutaneous gamma/delta T-cell lymphoma, CD8+ AECTCL: CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, acral CD8+ TCLPD: CD8+ acral T-cell lymphoproliferative disorder, CD4+ SMCLPD: CD4+ small or medium T-cell lymphoproliferative disorder.